Multiple Companies Selected for ChinaVenture's 2022 Best Investment Cases | Xinwen NEWS

In the "ChinaVenture 2022 Annual Rankings" released yesterday, three companies previously backed by Heart Capital were named among the best investment cases in their respective industries.

StoneWise

China AI and Big Data Industry

Top 10 Best Investment Cases

Micro-Nano Satellite

China Advanced Manufacturing and High-Tech Industry

Top 10 Best Investment Cases in Advanced Manufacturing

METiS Pharmaceuticals

China Healthcare and Medical Services Industry

Top 10 Best Investment Cases in Biopharma

StoneWise is a technology company dedicated to AI-driven new drug R&D. It aims to bring fresh perspectives to the pharmaceutical industry through technology and innovation, building a world-leading small-molecule innovative drug development platform. Drawing on deep expertise in drug discovery, innovative data integration methods, and strong software and engineering capabilities, the company has built an integrated technology platform centered on target pocket research, molecular generation, ultra-high-throughput virtual screening, rational design, and druggability optimization — improving efficiency and success rates across multiple critical stages from hit identification to preclinical candidate selection.

StoneWise brings together experts and talent from pharmaceuticals, AI, and internet sectors both in China and abroad, with formidable scientific research and product development capabilities. Since its founding, the company has established broad partnerships with universities, research institutions, and pharmaceutical companies at home and abroad, underpinned by a validated business model, solid technical foundations, and a well-rounded team.

Micro-Nano Satellite is among the earliest Chinese satellite system developers focused primarily on satellite manufacturing. It mainly engages in whole-satellite R&D and manufacturing, providing on-orbit delivery services. The company develops proprietary satellite platforms and core components, with capabilities spanning whole-satellite design, production, assembly, integration, and testing. It also has payload development capabilities for communications, optical remote sensing, and microwave remote sensing, with proven ability to lead and coordinate complex systems. Its self-developed satellite ground communication terminals and gateway stations, together with experience in satellite ground communication system integration, enable it to provide satellite resource-based integrated space-ground information system solutions for national defense, industry, and regional users.

To date, Beijing Micro-Nano Satellite Technology Co., Ltd. has successfully launched 17 satellites, ranging from 10 kg to 2 metric tons, including optical and remote sensing satellites such as Weina-1, Star Era, Tianyan, Taijing-3 01, and Taijing-4 01, as well as Ka-band communications satellites and a science experiment satellite for CCTV's "Cheer to the Future" program.

METiS Pharmaceuticals is the world's first biotechnology company to apply AI to drug delivery and drug discovery, combining artificial intelligence, machine learning, and quantum simulation to achieve more effective design of novel delivery materials, candidate drug selection, formulation design, and development of "programmable nucleic acid drugs" with nucleic acid delivery systems. Its core team is led by a member of the US National Academy of Engineering and multiple MIT scientists, comprising drug development experts from Regeneron, Amgen, and Novartis alongside rising talent in AI and computational sciences. At the 7th Future Healthcare VB100 Conference concluded earlier this month, METiS earned a spot on the 2023 Future Healthcare VB100 Main List — "China Innovative Biopharma Ranking" at #9, recognized for its industry-leading AI+drug delivery and drug discovery technology and the broad market potential of its dual-track model combining proprietary and partnered development.

Founded in 2022, Heart Capital is a China-based early-stage venture capital fund focused on technology and digitalization, established by Yan Han, formerly a founding partner at Lightspeed. The Heart Capital team consists mainly of Lightspeed China's founding partner, CFO, core investors, and seasoned industry investors from Cainiao and Baidu. The team's prior investments include Series A rounds in Full Truck Alliance (NYSE: YMM), Xpeng Motors (NYSE: XPEV, HK: 09868), as well as FinVolution (NYSE: FINV), 06810.HK, RoboSense, World Logistics, LandSpace, Lanhu, Micro-Nano Satellite, Starfield, and others. Rooted in China with a global outlook, Heart Capital seeks to find world leaders who will disrupt the future. The firm champions the value of "people" and "heart," and looks forward to accompanying more young Chinese entrepreneurs onto the world stage.